Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from PFE

Top 3 Dividend Achievers for October: High Yields, Growth Ahead

High-yield Dividend Achievers, such as United Parcel Service, Verizon, and Pfizer, offer attractive entry points in October for income investors.

Pfizer Shares Are Trading Higher Wednesday: What's Going On?

Pfizer (NYSE:PFE) shares are trading higher Wednesday after President Donald Trump announced a drug-pricing deal with the company.

Stock Of The Day: Will Pfizer Head Higher?

Shares of Pfizer Inc. (NYSE:PFE) continue to head higher on Wednesday, a day after the company announced that it has secured a three-year grace period from President Donald Trump's tariffs on pharmaceuticals. This will enable Pfizer to offer its medication at significantly discounted prices compared to current rates.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Pfizer's TrumpRx Pact Sends Shockwaves: Why UnitedHealth, Lilly And CVS Can't Look Away

Pfizer Inc's (NYSE:PFE) deal with Washington isn't just a handshake in the Oval Office — it's a seismic jolt to America's drug-pricing game. By agreeing to sell medicines on the government's new TrumpRx platform at steep discounts and extend "most favored nation" (MFN) pricing to Medicaid, Pfizer bought itself a…

Lithium Americas, Nike, Pfizer, CoreWeave And Occidental Petroleum: Why These 5 Stocks Are On Investors' Radars Today

The U.S. stock market brushed aside worries over a potential government shutdown and advanced on Tuesday. The Dow Jones Industrial Average gained nearly 0.2% to 46,397.89, the SP 500 climbed about 0.4% to 6,688.46, and the Nasdaq rose 0.3% to 22,660.These are the top stocks that gained the attention of…

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk

The U.S. pharmaceutical industry is at the center of a policy maelstrom. President Donald Trump on Sep 25, put a 100% tariff on imported branded and patented medicines starting from Oct 1 with threats that tariffs might go up to as much as 250% in future. The instant market impact…

Pfizer Faces Court Over Depo-Provera Brain Tumor Claims

Pfizer Inc. (NYSE: PFE) faces mounting legal challenges over claims that its contraceptive injection Depo-Provera (DMPA) is linked to brain tumors, with a key court hearing set for late September that could determine whether affected women can pursue their cases in court.

inkl

Read news from The Economist, FT, and more,
with one subscription

Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel'

Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel'

President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current medical recommendations.

Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal

Pfizer Inc. (NYSE:PFE) on Monday agreed to acquire Metsera, Inc. (NASDAQ:MTSR) to accelerate the next generation of medicines for obesity and cardiometabolic diseases.

Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths

Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump administration health officials intend to link the vaccines to 25 child deaths. This assertion is reportedly based on unverified submissions to the Vaccine…

Patriots for Europe submit no-confidence motion against the European Commission

Patriots for Europe submit no-confidence motion against the European Commission

The Eurosceptic group has collected enough signatures to kick off a motion of censure. Von der Leyen will face Parliament’s verdict in October.

Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) reported topline Phase 3 results for their LP.8.1-adapted monovalent COMIRNATY (2025-2026 Formula) in high-risk adults.

Fresh no-confidence votes stalk EU's Ursula von der Leyen

Fresh no-confidence votes stalk EU's Ursula von der Leyen

The radical Left and far-right are about to present two different motions of censure against the Commission. A first vote is expected in October.

European Parliament seeks recovery from Patriots of EU funds misused by previous far-right group

European Parliament seeks recovery from Patriots of EU funds misused by previous far-right group

The group that includes France’s Rassemblement National, Italy’s The League, and Hungary’s Fidesz could be obliged to repay over €4 million.

Get all your
news in one place.

100's of premium titles.
One news app.

Is Pfizer Stock Underperforming the Nasdaq?

Although Pfizer has underperformed the Nasdaq recently, analysts remain moderately optimistic about the stock’s prospects.

Bernie Sanders Demands Health Secretary RFK Jr.'s Resignation As CDC Leadership Crisis Deepens

Senator Bernie Sanders (I-VT) called for Health and Human Services Secretary Robert F. Kennedy Jr.‘s resignation on Saturday, citing Kennedy’s “dangerous policies” that are “endangering the health of the American people.”

RFK Jr. Rescinds Emergency Authorizations For COVID-19 Vaccines

Health and Human Services Secretary Robert F. Kennedy Jr. announced on social media that the emergency use authorizations for COVID-19 vaccines have now been rescinded.

Unusual Put Option Activity in Pfizer Stock - Have Investors Turned Bearish?

Barchart reports that Pfizer stock is showing unusual put option activity in yesterday's trading. Does that mean investors have turned bearish? Not necessarily, especially given the company's upgraded guidance.

Get all your
news in one place.

100's of premium titles.
One news app.

Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease

Pfizer Inc. (NYSE:PFE) on Friday released results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 years of age and older with sickle cell disease.

3 Long-Term Dividend Buys You Can Get for Under $50

Discover three undervalued dividend stocks under $50 that offer income, growth potential, and strong total returns for value investors

Pfizer Raises Its Guidance and Analysts Up Their Targets - PFE Stock Looks Cheap

Pfizer stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just over 8x this year's estimates and 7.8x next year. That's too cheap. Shorting puts works here.

FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply

Pfizer Stock Is a Value Play Ahead of Earnings - Investors Can Short PFE Puts for Income

Pfizer stock still looks cheap ahead of its upcoming Q2 earnings release on Aug. 5. Moreover, investors can make extra income by selling out-of-the-money (OTM) put options.

Pfizer Stock: Analyst Estimates & Ratings

Pfizer has lagged behind the broader market over the past year, but analysts maintain a cautiously optimistic outlook on the stock’s future performance.

Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound

The entire healthcare sector has fallen into a deeply discounted valuation, creating opportunities for investors who hunt for value and upside

1 2 3 4 5

People

179,101 stories

Robert F. Kennedy Jr

Ursula von der Leyen

Elizabeth Warren

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

the European Commission

European Parliament

the European Parliament

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Government Shutdown

Dow Jones Industrial Average

Sickle Cell Disease

Places

359,074 stories

Washington D.C.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play